In 2015, Bradner’s group used JQ1 and thalidomide (a ligand for CRBN E3 ligase) to develop the BRD4-targeting PROTAC dBET1 with a DC50 value of 430 nM, attenuating tumor progression in vitro and in vivo by reducing the expression of BRD4 and c-myc [12]. Here, BRD4 is linked to neoplasm.